Opinion|Videos|January 12, 2026
SUMMIT Trial: Key Data for Bezuclastinib in Non-Advanced Systemic Mastocytosis
Author(s)Lindsay Rein, MD, Frederick Lansigan, MD
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss data from the SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis.
Advertisement
Episodes in this series
Lindsay Rein, MD, and Frederick Lansigan, MD, review key efficacy and safety data from the SUMMIT trial evaluating bezuclastinib (CGT9486) in patients with non-advanced systemic mastocytosis. They highlight improvements in symptom burden, mast cell activity, and relevant clinical endpoints. Rein and Lansigan discuss how these findings contribute to the growing evidence base supporting targeted KIT inhibition.
Advertisement
Related to this article
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Judy E. Garber, MD, MPH, of the Dana Farber Cancer Institute is the recipient of the 2026 Basser Global Prize.
The European Commission approved T-DXd for patients with HER2+ breast cancer who have residual invasive disease after neoadjuvant treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5